COVID-19 vaccine hesitancy among pregnant and postpartum Kenyan women.
COVID-19
Kenya
postpartum
pregnancy
vaccination
vaccine hesitancy
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
04
02
2023
received:
12
08
2022
accepted:
20
03
2023
pmc-release:
01
07
2024
medline:
19
6
2023
pubmed:
11
4
2023
entrez:
10
4
2023
Statut:
ppublish
Résumé
The authors evaluated factors contributing to coronavirus disease 2019 (COVID-19) vaccine hesitancy among pregnant and postpartum women to inform vaccine scale-up strategies. This observational study utilized data from pregnant and postpartum women attending four public maternal child health (MCH) clinics in Western Kenya. From October 2020 to July 2022, nurses assessed COVID-19 vaccine hesitancy, defined as reporting "unlikely" or "very unlikely" to the question, "If a vaccine for COVID-19 were available today, what is the likelihood that you would get vaccinated?" Among 1023 women (235 pregnant, 788 postpartum), 20% reported worsened MCH care during the pandemic and most (92%) perceived themselves or family members to be at risk for COVID-19, yet 54% of women reported COVID-19 vaccine hesitancy. Vaccine hesitancy was more frequent among women reporting worsened MCH care (P < 0.001) since the pandemic and those who did not trust the government as a source of COVID-19 information (P = 0.016). Over the 2-year period, willingness to receive the vaccine almost doubled (38% to 71%, P < 0.001). Our findings suggest that sustaining access to quality MCH services may decrease COVID-19 vaccine hesitancy. Willingness to receive the vaccine doubled over the 2-year period in our cohort, suggesting increased trust for use and acceptance in the unique context of the pregnancy/postpartum period.
Identifiants
pubmed: 37036449
doi: 10.1002/ijgo.14773
pmc: PMC10330087
mid: NIHMS1892805
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-153Subventions
Organisme : NIAID NIH HHS
ID : R01 AI125498
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR019220
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD100201
Pays : United States
Organisme : NINR NIH HHS
ID : R01NR019220
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD108041
Pays : United States
Informations de copyright
© 2023 International Federation of Gynecology and Obstetrics.
Références
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Reprod Health. 2021 Jan 18;18(1):10
pubmed: 33461593
Front Sociol. 2021 Apr 07;6:613042
pubmed: 33898553
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724
Immunity. 2020 May 19;52(5):737-741
pubmed: 32433946
Front Glob Womens Health. 2020 Nov 26;1:599267
pubmed: 34816169
Lancet. 2020 May 30;395(10238):1735-1738
pubmed: 32386564
JAMA Netw Open. 2022 Jun 1;5(6):e2219133
pubmed: 35763300
Public Health Action. 2021 Mar 21;11(1):12-21
pubmed: 33777716
PLoS One. 2021 Mar 26;16(3):e0249214
pubmed: 33770120
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):259-265
pubmed: 28777265
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
BMC Public Health. 2021 Feb 3;21(1):276
pubmed: 33536001
Am J Obstet Gynecol. 2020 May;222(5):415-426
pubmed: 32105680